Categories Technology
IPO: This online retailer is going public tomorrow, and investors are thrilled
We are seeing some back-to-back tech IPOs this week, with cybersecurity firm Crowdstrike (NASDAQ: CRWD) getting an overwhelming response on Wednesday and freelancing platform Fiverr hitting the market on Thursday.
Closely following them is e-commerce firm Chewy, which sells pet food and other pet-related products. The company will start trading under the ticker symbol CHWY on the New York Stock Exchange on Friday.
The company had initially expected to price its 41.6 million shares in the range of $17 to $19, but considering the strong investor demand, raised it to $19 to $21. At the top end of this price range, the company would be valued at approximately $8.4 billion.
The company is eyeing $870 million in net proceeds from the IPO, which it says would be used for general corporate purposes.
The Dania Beach, Florida-based firm had recorded $3.5 billion in revenues last year, a 67% jump year-over-year. This is an increase from around $26 million in 2012. However, the company has not been profitable and recorded $267.9 million in 2018.
READ: Things to know as Crowdstrike makes a scintillating market debut
According to its SEC filing, for the quarter ended May 5, 2019, the company has projected revenues of $1.11 billion, a 45% increase from the same period last year, helped by customer growth. Chewy also said it expects to cut down its net losses to $29.5 million during this period, which is almost half of what it reported last year.
Founded in 2011, Chewy.com was acquired by retail chain PetSmart in 2017, reportedly for $3.35 billion. It was later spun off, but PetSmart continues to be a major stakeholder in the Chewy.
Chewy says it has over 45,000 products on is website from over 1,600 brands. Almost half of its revenues come from the sale of pet food, while the rest come from medicines and vet care products.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
